Factors affecting responsiveness to hepatitis B immunization in dialysis patients

Basit Öğe Kaydı
dc.authoridAKIN, Davut/0000-0002-9567-7940
dc.authoridCatak, Binali/0000-0003-2769-990X
dc.authoridAYDIN, MEHTAP/0000-0003-4044-9366
dc.authoridASAN, ALI/0000-0002-8856-7356
dc.contributor.authorAsan, Ali
dc.contributor.authorDemirhan, Huriye
dc.contributor.authorSorkun, Hulya Cetin
dc.contributor.authorOzkan, Sevgi
dc.contributor.authorAydin, Mehtap
dc.contributor.authorAkin, Davut
dc.contributor.authorTatar, Bengu
dc.date.accessioned2025-01-27T20:35:07Z
dc.date.available2025-01-27T20:35:07Z
dc.date.issued2017
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractHepatitis B virus (HBV) and hepatitis C virus (HCV) infections are widespread health problems all over the world and have high morbidity and mortality. Hemodialysis patients are more frequently exposed to these viruses as they have poor immune system and frequently undergo parenteral interventions. The vaccination against HBV prevents infection and it has been recommended for the prevention of HBV infection in all susceptible dialysis patients. This study aimed to determine the seroprevalence of HBV and HCV infections and analyzed the factors affecting inadequate response to HBV vaccine in dialysis patients. The data for 584 dialysis patients that were followed up at seven dialysis centers were analyzed. The patients received four doses of 40 mu g recombinant hepatitis B vaccine at 0, 1, 2, and 6 months and were tested for anti-HBs titer after one month of completion of vaccination. If patients showed a titer of anti-HBs < 10 IU/mL, an additional 40 mu g in four vaccine doses was administered immediately and they were retested for the anti-HBs following the same schedule. The patients were divided into two groups: responders and non-responders. HBsAg and anti-HCV seroprevalence was 3.4% and 10.3%, respectively. After vaccination schedule, 264 (83.5%) patients had antibody response to HBV vaccine and 52 (16.5%) had no response. Hepatitis B vaccine unresponsiveness is more common in the patients with hepatitis C positivity (p = 0.011), BMI > 30 (p = 0.019), over the age of 65 years (p = 0.009), and duration of dialysis treatment > 5 years (p = 0.001). There was no statistically significant difference between gender, causes of renal disease, erythropoietin treatment, and the type of dialysis. Hepatitis C infection, obesity, being elderly, and having long hemodialysis period reduced the hepatitis B vaccination response in hemodialysis patients.
dc.identifier.doi10.1007/s11255-017-1616-9
dc.identifier.endpage1850
dc.identifier.issn0301-1623
dc.identifier.issn1573-2584
dc.identifier.issue10
dc.identifier.pmid28620716
dc.identifier.startpage1845
dc.identifier.urihttps://doi.org/10.1007/s11255-017-1616-9
dc.identifier.urihttps://hdl.handle.net/20.500.12428/23573
dc.identifier.volume49
dc.identifier.wosWOS:000411172500018
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofInternational Urology and Nephrology
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectHemodialysis
dc.subjectHepatitis B virus vaccine
dc.subjectHepatitis C
dc.subjectUnresponsiveness
dc.titleFactors affecting responsiveness to hepatitis B immunization in dialysis patients
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu